GeneDx Holdings Corp. - Asset Resilience Ratio
GeneDx Holdings Corp. (WGS) has an Asset Resilience Ratio of 15.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See WGS working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how GeneDx Holdings Corp.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is GeneDx Holdings Corp.'s balance sheet.
Liquid Assets Composition Over Time
This chart breaks down GeneDx Holdings Corp.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read WGS total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $72.23 Million | 15.0% |
| Total Liquid Assets | $72.23 Million | 15.00% |
Asset Resilience Insights
- Good Liquidity Position: GeneDx Holdings Corp. maintains a healthy 15.00% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
GeneDx Holdings Corp. Industry Peers by Asset Resilience Ratio
Compare GeneDx Holdings Corp.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468 |
Diagnostics & Research | 15.34% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for GeneDx Holdings Corp. (2022–2025)
The table below shows the annual Asset Resilience Ratio data for GeneDx Holdings Corp..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.63% | $66.28 Million | $570.19 Million | -1.72pp |
| 2024-12-31 | 13.35% | $55.97 Million | $419.38 Million | +6.07pp |
| 2023-12-31 | 7.28% | $30.47 Million | $418.76 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $545.26 Million | -- |
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and can… Read more